Latest news with #TobyMaher
Medscape
28-05-2025
- Business
- Medscape
Deupirfenidone Shows Promise Against IPF-Linked Lung Decline
SAN FRANCISCO — A molecular variant of an older, hard-to-tolerate antifibrotic agent showed promise for reducing decline in forced vital capacity (FVC) over 26 weeks among patients with idiopathic pulmonary fibrosis (IPF). These findings come from the phase 2B ELEVATE IPF trial, results of which were reported at the American Thoracic Society (ATS) 2025 International Conference here. The trial compared the investigational agent deupirfenidone to placebo for protection against FVC decline in 257 patients with IPF. The deupirfenidone molecule is nearly identical in conformation to pirfenidone, except for the substitution of hydrogen in pirfenidone for deuterium, or 'heavy hydrogen,' in deupirfenidone at the site of metabolism. This process, known as 'deuteration,' is designed to make the modified compound less toxic than pirfenidone, said lead investigator Toby Maher, MD, PhD, from the Keck School of Medicine at the University of Southern California, Los Angeles. Although the primary endpoint of the study was decline in FVC over 26 weeks, 'when we've looked at the open-label extension of patients continuing on the high dose, we've seen a sustained stabilization in FVC over 52 weeks, again suggesting a durable effect of treatment,' he said in an oral abstract session. Multinational Trial In the ELEVATE IPF trial, 257 patients with IPF from 87 sites in 14 countries were enrolled and randomly assigned to one of four treatment arms: 550 mg deupirfenidone thrice per day, 825 mg deupirfenidone thrice per day, 801 mg pirfenidone thrice per day, or placebo thrice per day. The primary Bayesian analysis showed that the mean adjusted change in FVC from baseline to 26 weeks was −48.4 ml for all patients randomized to deupirfenidone compared with −110.7 ml for patients assigned to placebo (posterior probability vs placebo, 98.5%). The respective adjusted mean changes from baseline in FVC% predicted were −48.4% and −1.1% (posterior probability, 99.6%). In a Frequentist inference analysis, compared with placebo the higher dose of deupirfenidone but not the lower dose was associated with significantly less decline in FVC and FVC% predicted. The adjusted mean changes over baseline were −21.5 ml for the 825 mg deupirfenidone group vs −112.5 ml for the placebo group ( P = .02), and the respective changes in FVC% predicted were −21.5% and −3.43% ( P = .01). Both pirfenidone and deupirfenidone 825 mg (but not 550 mg) significantly delayed time to progression compared with placebo. The respective hazard ratios were 0.50 ( P = .0076) and 0.439 ( P = .0033). In the placebo, pirfenidone, deupirfenidone 550 mg and 825 mg arms, respectively, treatment-emergent adverse events commonly associated with antifibrotics were nausea (7.7%, 27.0%, 16.9%, 20.3%), dyspepsia (3.1%, 22.2%, 12.3%, 14.1%), diarrhea (9.2%, 11.1%, 10.8%, 7.8%), abdominal pain (4.6%, 7.9%, 6.2%, 14.1%), photosensitivity reaction (0%, 7.9%, 6.2%, 7.8%), decreased appetite (7.7%, 14.3%, 18.5%, 20.3%), fatigue (1.5%, 11.1%, 7.7%, 9.4%), dizziness (3.1%, 7.9%, 9.2%, 12.5%), and headache (4.6%, 12.7%, 7.7%, 3.1%). GI Signal In the question and answer, session co-moderator Rachel Knipe, MD, from Massachusetts General Hospital in Boston, commented that there appeared to be a small signal for increased abdominal pain with deupirfenidone but less so for diarrhea and other gastrointestinal symptoms. She asked Maher whether investigators had also looked at liver function tests. 'The liver function tests didn't flag up as an adverse event that differed across groups or reached the threshold for inclusion in the table,' Maher said. Maher acknowledged that there are gastrointestinal events associated with the drug, but added that it's difficult to distinguish specific events from one another. 'The challenge with clinical trials in interpreting adverse events is that we are beholden on the individual investigators to label the side effects,' he said, noting that one center's dyspepsia, may be another center's loss of appetite or abdominal pain. In an interview, Medscape Medical News asked Knipe, whose laboratory at Mass General has a special focus on PF, for her impression of deupirfenidone. 'I think the data looks pretty good; it's exciting, and it looks like it has good effect on lung function,' she said, adding that the adverse event profile appears to be more favorable than that of pirfenidone. The study was funded by PureTech Health. Maher reported receiving grants and funding and serving as a consultant for the company and others. Knipe had no disclosures relevant to the study.
Yahoo
22-05-2025
- Business
- Yahoo
Vicore Presents New Data at the 2025 American Thoracic Society International Conference
STOCKHOLM, SE / / May 22, 2025 / Vicore Pharma Holding (STO:VICO) - Stockholm, May 22, 2025 - Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced that the company delivered multiple oral presentations and posters this week at the 2025 American Thoracic Society (ATS) International Conference, held May 16-21, 2025. "The presentations at this year's ATS conference underscore the momentum building around our innovative approach to the treatment of idiopathic pulmonary fibrosis (IPF)," said Bertil Lindmark, MD, PhD, Chief Medical Officer of Vicore. "We are proud to share compelling new data that highlight the potential of buloxibutid to address critical unmet needs and offer a differentiated, disease-modifying therapy for patients suffering from IPF." The AIR Phase 2 Trial of the Angiotensin II Type 2 Receptor Agonist, Buloxibutid, in Individuals With Idiopathic Pulmonary Fibrosis: A Responder Analysis In an oral presentation, Toby Maher, MD, PhD, provided further detail from the Phase 2a AIR trial evaluating buloxibutid in IPF, including an analysis of the response pattern in percent predicted forced vital capacity (ppFVC) and a Synthetic Control Arm (SCA) analysis utilizing real world data from a large cohort of IPF patients. A key finding in the Phase 2a AIR trial was that a substantial proportion of participants demonstrated improvement in lung function. An analysis comparing the proportion of patients experiencing improvement in lung function at 0, 5 and 10 ppFVC in the Phase 2a AIR trial with the Phase 3 studies leading to the approval of the current standard of care compared favorably with those for the approved antifibrotic agents. In addition to the responder analysis, Dr. Maher presented a SCA drawn from a pool of over 10,000 real world IPF patients on the Qureight platform and tightly matched to the Phase 2a AIR population using a Monte Carlo cross validation analysis. Comparison of forced vital capacity (FVC) in these SCAs to the impact of buloxibutid on FVC in the Phase 2a AIR trial revealed a robust treatment effect with a high degree of statistical significance (p=.0025). Buloxibutid Potently Inhibits Fibrosis Biomarkers in the Scar-in-a-Jar Primary Human Lung Fibroblast Assay View poster In a human lung fibroblast assay, buloxibutid demonstrated potent and dose-dependent inhibition of PRO-C3 a key biomarker reflecting fibrotic progression, at concentrations reached systemically with clinical doses of the drug candidate. In comparison, clinically relevant concentrations of nintedanib did not inhibit PRO-C3 and nerandomilast showed limited impact on PRO-C3 across all tested concentrations, including concentrations in the clinically relevant range. The superior in vitro performance of buloxibutid compared to nintedanib and nerandomilast on IPF biomarkers associated with fibrotic progression highlights robust anti-fibrotic activity and positions it as a competitive next-generation IPF therapy. ASPIRE Trial in Idiopathic Pulmonary Fibrosis: A Patient Experience-focused Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Trial of the Novel Angiotensin II Type 2 Receptor Agonist Buloxibutid View poster Tamera Corte, MD, PhD, presented the design of the Phase 2b ASPIRE trial evaluating the efficacy and safety of buloxibutid in IPF and highlighted its patient-friendly features. ASPIRE is currently ongoing in fourteen countries. To improve patient participation and retention, a patient and caregiver panel consisting of six IPF patients and two caregivers was established during the trial design process. The panel provided feedback and advised on the ASPIRE trial design, trial conduct, and patient-facing materials. The panel assisted in optimizing the trial design by suggesting fewer site visits and supplementing essential in-person visits with telephone visits to ensure patient safety and promote engagement. In addition, semi-structured interviews were added during the trial with a subgroup of 10-14 participants to provide feedback on the trial participation experience. This feedback played a critical role in shaping the design of the Phase 2b ASPIRE trial to prioritize patient experience while maintaining scientific rigor. A Digital Psychological Therapy Improves Health-related Quality of Life in Pulmonary Fibrosis Patients Using Antifibrotic Treatment In an oral presentation, Joshua Solomon, MD, provided an overview of the COMPANION trial, a randomized, controlled, open-label trial investigating the efficacy of the digital therapeutic, Almee TM , in patients with pulmonary fibrosis and anxiety symptoms. Treatment with Almee, the first pulmonary fibrosis-specific digital psychotherapy, significantly improved psychological health, as reflected in Health-Related Quality of Life scores, in participants with pulmonary fibrosis, whether taking antifibrotic treatment or not. For further information, please contact: Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, Jeppsson, CFO, tel: +46 70 553 14 65, About Vicore PharmaVicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. The company is publicly listed on the Nasdaq Stockholm exchange (VICO). AttachmentsVicore Presents New Data at the 2025 American Thoracic Society International Conference SOURCE: Vicore Pharma Holding View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
PureTech's Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression Detailed safety analysis underscores favorable tolerability profile for deupirfenidone PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end BOSTON, May 20, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the successful Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone's treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF). "The ELEVATE IPF trial is one of the most promising Phase 2 studies we've seen in IPF in recent years," said Toby Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, and lead investigator in the ELEVATE IPF trial. "The ability for a monotherapy to reduce lung function decline close to a level seen in healthy older adults, and to sustain that effect over time without compromising tolerability, is not something we have seen with currently available therapies. Deupirfenidone has the potential to raise the bar for what patients and physicians can expect from IPF treatment." Data presented from PureTech's global Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging ELEVATE IPF trial demonstrated the potential for deupirfenidone to offer a differentiated treatment option for patients with IPF. In the trial, patients treated with deupirfenidone 825 mg three times a day (TID) experienced a slower rate of lung function decline,1 as measured by Forced Vital Capacity (FVC), at 26 weeks versus those who were treated with placebo (-21.5 mL vs. -112.5 mL, respectively; p=0.02).2 This statistically significant difference represents a robust treatment effect versus placebo of 80.9% for deupirfenidone 825 mg TID as a monotherapy. This result compares favorably against the rate of decline in FVC observed in the trial among patients treated with pirfenidone 801 mg TID versus placebo (-51.6 mL vs. -112.5 mL, respectively), which was consistent with previously reported pirfenidone clinical trial data3 and represents a treatment effect of 54.1%. Taken together, these results indicate that the treatment effect with deupirfenidone 825 mg TID was approximately 50% greater than that of pirfenidone 801 mg TID, based on their respective reductions in lung function decline versus placebo (80.9% vs. 54.1%). In addition to these findings, deupirfenidone 825 mg TID also demonstrated a statistically significant benefit in delaying time to IPF progression4 compared to placebo (hazard ratio = 0.439; p=0.0023), further supporting the clinical relevance of the treatment effect. Importantly, the rate of FVC decline observed over 26 weeks with deupirfenidone 825 mg TID (-21.5 mL) was similar to the expected natural decline in lung function in healthy older adults (approximately -15.0 mL to -25.0 mL).5,6 Furthermore, preliminary data from the ongoing open-label extension (OLE) study suggest that this treatment effect is durable out to at least 52 weeks. As of May 9, 2025, a total of 101 patients had received at least 52 weeks of treatment with deupirfenidone. Those in the deupirfenidone 825 mg TID arm experienced a decline in FVC of -32.8 mL over the 52-week period,7 which is similar to the expected natural decline in lung function in healthy older adults over one year (approximately -30.0 mL to -50.0 mL).6 These new data provide additional support for the durability of the treatment effect observed with this dose and reinforce its potential to stabilize lung function decline over time, while maintaining favorable safety and tolerability. Additional details from the ongoing OLE are expected to be shared in a future scientific forum. These results are further supported by preliminary pharmacokinetic (PK) data, which underscore the differentiated profile of deupirfenidone. Compared to pirfenidone 801 mg TID, deupirfenidone 825 mg TID resulted in an approximately 50% increase in drug exposure. Notably, the dramatically increased drug exposure did not result in an increase in tolerability challenges, suggesting that the deuterated structure of deupirfenidone may overcome the dose-limiting adverse events associated with pirfenidone. PureTech believes these PK results are consistent with the enhanced efficacy and favorable tolerability seen with deupirfenidone 825 mg TID in the trial. "The IPF community has long needed therapies that can provide meaningful efficacy without compromising tolerability," said Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer of PureTech. "Data from our Phase 2b trial and open-label extension study suggest that deupirfenidone may slow lung function decline in a way that more closely mirrors the natural aging process, and that this effect is durable. These data are quite remarkable and – to our knowledge – this level of efficacy has not been observed with other monotherapies. These findings further support our belief that deupirfenidone may offer a substantially differentiated treatment option for people living with IPF and support its potential to become a new standard of care." Deupirfenidone was well tolerated at both doses studied. Safety analyses included identification of the 16 most common treatment-emergent adverse events (TEAEs), defined as occurring in more than 5% of participants in at least one treatment group, and characterized the arm with the highest relative incidence of each of these 16 TEAEs. The pirfenidone 801 mg treatment group had the highest relative incidence for 9 of these TEAEs, followed by deupirfenidone 825 mg (5), placebo (2), and deupirfenidone 550 mg (0). "The results of the ELEVATE IPF trial demonstrate the potential for deupirfenidone to address the persistent suboptimal efficacy offered by current standard-of-care treatments for IPF, without sacrificing tolerability," Camilla Graham, M.D., M.P.H., Senior Vice President of Medical Affairs at PureTech. "We are excited to continue development of deupirfenidone to meaningfully improve the lives of patients living with IPF." PureTech is targeting a meeting with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the Phase 2b trial and align on a potential registrational pathway, with the goal of initiating a Phase 3 trial by the end of 2025. PureTech anticipates providing further guidance later this year following the finalization of the trial design and FDA interactions. About the ELEVATE IPF TrialThe Phase 2b ELEVATE IPF trial was a global, randomized, double-blind, active- and placebo-controlled, dose-ranging trial designed to evaluate the efficacy, tolerability, safety and dosing regimen of deupirfenidone (LYT-100) in patients with IPF compared to placebo. 257 participants were randomized in a ratio of 1:1:1:1 to receive either 550 mg of deupirfenidone, 825 mg of deupirfenidone, 801 mg pirfenidone or placebo three times a day (TID) for 26 weeks. Participants who completed the trial had the option to enroll in an open-label extension, which is ongoing. The primary endpoint of the trial was the rate of decline in Forced Vital Capacity (FVC) for the combined deupirfenidone arms versus placebo over the 26-week treatment period. FVC is a measure of the maximum amount of air (in mL) that an individual can forcibly exhale after fully inhaling. It is a standard measurement in clinical trials for IPF and is used to assess disease progression as well as to predict mortality. A prespecified Bayesian analysis was utilized to assess the primary endpoint and provided a posterior probability, which is the probability of superior efficacy for deupirfenidone compared to placebo. This also allowed for augmentation of the placebo arm with placebo data from historical IPF trials. This approach enabled a more patient-centric clinical trial design by minimizing the number of trial participants exposed to placebo – a key consideration since IPF is progressive and fatal – while delivering a robust, placebo-controlled dataset. About Deupirfenidone (LYT-100)Deupirfenidone (LYT-100) is an investigational therapy in development as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). It is a deuterated form of pirfenidone, which – along with nintedanib – is one of the two FDA-approved treatments for IPF. Despite achieving blockbuster status, the current SOC treatments only modestly slow lung function decline, with tolerability limiting the ability to achieve higher doses. This results in suboptimal efficacy, reduced patient uptake, and poor adherence – all due to a tolerability ceiling that prevents dosing levels that could significantly improve patient outcomes. Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining safety and tolerability – a result not previously achieved by other investigational or marketed IPF therapies to the Company's knowledge. These findings support the potential for deupirfenidone to offer a meaningful advance for patients living with this progressive and life-limiting disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic diseases, including progressive fibrosing interstitial lung diseases and other fibrotic conditions. About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive and fatal lung disease characterized by irreversible scarring of lung tissue. Median survival following diagnosis is estimated to be two to five years.8 IPF affects more than 230,000 people across the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom).9 Although two therapies are approved to treat IPF, their use remains limited, and nearly three out of four people with IPF in the United States have never received either treatment.10 There remains a significant need for therapies that can more effectively slow or stabilize disease progression, while maintaining favorable tolerability, to improve outcomes for people living with IPF. About PureTech HealthPureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking StatementsThis press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the deupirfenidone (LYT-100) development program and development plans, its potential benefits to patients, plans for discussions with regulatory authorities, the further development of the program, future presentation of additional data from the trial and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. References 1 Efficacy analysis used a random coefficient regression model with absolute FVC including baseline as response variable and week, treatment and interaction between week and treatment as fixed effect. The analysis was performed based on the predefined Full Analysis Set. 2 All p values are two-sided and have not been corrected for multiplicity. 3 Roche. (2014). Esbriet® (pirfenidone) prescribing information. U.S. Food and Drug Administration. 4 IPF progression was defined as a ≥5% decline in FVCpp or death. 5 FVC decline at 6 months was estimated assuming linear decline over time. 6 Valenzuela, C., Bonella, F., Moor, C., Weimann, G., Miede, C., Stowasser, S., & Maher, T. (2024, September). Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references [Poster presentation]. European Respiratory Society International Congress, Vienna, Austria; and Luoto, J., Pihlsgård, M., Wollmer, P., & Elmståhl, S. (2019). Relative and absolute lung function change in a general population aged 60–102 years. European Respiratory Journal, 53(3), 1701812. View source version on Contacts PureTech Public Relationspublicrelations@ Investor Relationsir@ UK/EU MediaBen Atwell, Rob Winder+44 (0) 20 3727 1000puretech@ US MediaJustin Chen+1 609 578 7230jchen@
Yahoo
20-05-2025
- Business
- Yahoo
PureTech's Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression Detailed safety analysis underscores favorable tolerability profile for deupirfenidone PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end BOSTON, May 20, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the successful Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone's treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF). "The ELEVATE IPF trial is one of the most promising Phase 2 studies we've seen in IPF in recent years," said Toby Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, and lead investigator in the ELEVATE IPF trial. "The ability for a monotherapy to reduce lung function decline close to a level seen in healthy older adults, and to sustain that effect over time without compromising tolerability, is not something we have seen with currently available therapies. Deupirfenidone has the potential to raise the bar for what patients and physicians can expect from IPF treatment." Data presented from PureTech's global Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging ELEVATE IPF trial demonstrated the potential for deupirfenidone to offer a differentiated treatment option for patients with IPF. In the trial, patients treated with deupirfenidone 825 mg three times a day (TID) experienced a slower rate of lung function decline,1 as measured by Forced Vital Capacity (FVC), at 26 weeks versus those who were treated with placebo (-21.5 mL vs. -112.5 mL, respectively; p=0.02).2 This statistically significant difference represents a robust treatment effect versus placebo of 80.9% for deupirfenidone 825 mg TID as a monotherapy. This result compares favorably against the rate of decline in FVC observed in the trial among patients treated with pirfenidone 801 mg TID versus placebo (-51.6 mL vs. -112.5 mL, respectively), which was consistent with previously reported pirfenidone clinical trial data3 and represents a treatment effect of 54.1%. Taken together, these results indicate that the treatment effect with deupirfenidone 825 mg TID was approximately 50% greater than that of pirfenidone 801 mg TID, based on their respective reductions in lung function decline versus placebo (80.9% vs. 54.1%). In addition to these findings, deupirfenidone 825 mg TID also demonstrated a statistically significant benefit in delaying time to IPF progression4 compared to placebo (hazard ratio = 0.439; p=0.0023), further supporting the clinical relevance of the treatment effect. Importantly, the rate of FVC decline observed over 26 weeks with deupirfenidone 825 mg TID (-21.5 mL) was similar to the expected natural decline in lung function in healthy older adults (approximately -15.0 mL to -25.0 mL).5,6 Furthermore, preliminary data from the ongoing open-label extension (OLE) study suggest that this treatment effect is durable out to at least 52 weeks. As of May 9, 2025, a total of 101 patients had received at least 52 weeks of treatment with deupirfenidone. Those in the deupirfenidone 825 mg TID arm experienced a decline in FVC of -32.8 mL over the 52-week period,7 which is similar to the expected natural decline in lung function in healthy older adults over one year (approximately -30.0 mL to -50.0 mL).6 These new data provide additional support for the durability of the treatment effect observed with this dose and reinforce its potential to stabilize lung function decline over time, while maintaining favorable safety and tolerability. Additional details from the ongoing OLE are expected to be shared in a future scientific forum. These results are further supported by preliminary pharmacokinetic (PK) data, which underscore the differentiated profile of deupirfenidone. Compared to pirfenidone 801 mg TID, deupirfenidone 825 mg TID resulted in an approximately 50% increase in drug exposure. Notably, the dramatically increased drug exposure did not result in an increase in tolerability challenges, suggesting that the deuterated structure of deupirfenidone may overcome the dose-limiting adverse events associated with pirfenidone. PureTech believes these PK results are consistent with the enhanced efficacy and favorable tolerability seen with deupirfenidone 825 mg TID in the trial. "The IPF community has long needed therapies that can provide meaningful efficacy without compromising tolerability," said Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer of PureTech. "Data from our Phase 2b trial and open-label extension study suggest that deupirfenidone may slow lung function decline in a way that more closely mirrors the natural aging process, and that this effect is durable. These data are quite remarkable and – to our knowledge – this level of efficacy has not been observed with other monotherapies. These findings further support our belief that deupirfenidone may offer a substantially differentiated treatment option for people living with IPF and support its potential to become a new standard of care." Deupirfenidone was well tolerated at both doses studied. Safety analyses included identification of the 16 most common treatment-emergent adverse events (TEAEs), defined as occurring in more than 5% of participants in at least one treatment group, and characterized the arm with the highest relative incidence of each of these 16 TEAEs. The pirfenidone 801 mg treatment group had the highest relative incidence for 9 of these TEAEs, followed by deupirfenidone 825 mg (5), placebo (2), and deupirfenidone 550 mg (0). "The results of the ELEVATE IPF trial demonstrate the potential for deupirfenidone to address the persistent suboptimal efficacy offered by current standard-of-care treatments for IPF, without sacrificing tolerability," Camilla Graham, M.D., M.P.H., Senior Vice President of Medical Affairs at PureTech. "We are excited to continue development of deupirfenidone to meaningfully improve the lives of patients living with IPF." PureTech is targeting a meeting with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the Phase 2b trial and align on a potential registrational pathway, with the goal of initiating a Phase 3 trial by the end of 2025. PureTech anticipates providing further guidance later this year following the finalization of the trial design and FDA interactions. About the ELEVATE IPF TrialThe Phase 2b ELEVATE IPF trial was a global, randomized, double-blind, active- and placebo-controlled, dose-ranging trial designed to evaluate the efficacy, tolerability, safety and dosing regimen of deupirfenidone (LYT-100) in patients with IPF compared to placebo. 257 participants were randomized in a ratio of 1:1:1:1 to receive either 550 mg of deupirfenidone, 825 mg of deupirfenidone, 801 mg pirfenidone or placebo three times a day (TID) for 26 weeks. Participants who completed the trial had the option to enroll in an open-label extension, which is ongoing. The primary endpoint of the trial was the rate of decline in Forced Vital Capacity (FVC) for the combined deupirfenidone arms versus placebo over the 26-week treatment period. FVC is a measure of the maximum amount of air (in mL) that an individual can forcibly exhale after fully inhaling. It is a standard measurement in clinical trials for IPF and is used to assess disease progression as well as to predict mortality. A prespecified Bayesian analysis was utilized to assess the primary endpoint and provided a posterior probability, which is the probability of superior efficacy for deupirfenidone compared to placebo. This also allowed for augmentation of the placebo arm with placebo data from historical IPF trials. This approach enabled a more patient-centric clinical trial design by minimizing the number of trial participants exposed to placebo – a key consideration since IPF is progressive and fatal – while delivering a robust, placebo-controlled dataset. About Deupirfenidone (LYT-100)Deupirfenidone (LYT-100) is an investigational therapy in development as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). It is a deuterated form of pirfenidone, which – along with nintedanib – is one of the two FDA-approved treatments for IPF. Despite achieving blockbuster status, the current SOC treatments only modestly slow lung function decline, with tolerability limiting the ability to achieve higher doses. This results in suboptimal efficacy, reduced patient uptake, and poor adherence – all due to a tolerability ceiling that prevents dosing levels that could significantly improve patient outcomes. Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining safety and tolerability – a result not previously achieved by other investigational or marketed IPF therapies to the Company's knowledge. These findings support the potential for deupirfenidone to offer a meaningful advance for patients living with this progressive and life-limiting disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic diseases, including progressive fibrosing interstitial lung diseases and other fibrotic conditions. About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive and fatal lung disease characterized by irreversible scarring of lung tissue. Median survival following diagnosis is estimated to be two to five years.8 IPF affects more than 230,000 people across the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom).9 Although two therapies are approved to treat IPF, their use remains limited, and nearly three out of four people with IPF in the United States have never received either treatment.10 There remains a significant need for therapies that can more effectively slow or stabilize disease progression, while maintaining favorable tolerability, to improve outcomes for people living with IPF. About PureTech HealthPureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking StatementsThis press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the deupirfenidone (LYT-100) development program and development plans, its potential benefits to patients, plans for discussions with regulatory authorities, the further development of the program, future presentation of additional data from the trial and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. References 1 Efficacy analysis used a random coefficient regression model with absolute FVC including baseline as response variable and week, treatment and interaction between week and treatment as fixed effect. The analysis was performed based on the predefined Full Analysis Set. 2 All p values are two-sided and have not been corrected for multiplicity. 3 Roche. (2014). Esbriet® (pirfenidone) prescribing information. U.S. Food and Drug Administration. 4 IPF progression was defined as a ≥5% decline in FVCpp or death. 5 FVC decline at 6 months was estimated assuming linear decline over time. 6 Valenzuela, C., Bonella, F., Moor, C., Weimann, G., Miede, C., Stowasser, S., & Maher, T. (2024, September). Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references [Poster presentation]. European Respiratory Society International Congress, Vienna, Austria; and Luoto, J., Pihlsgård, M., Wollmer, P., & Elmståhl, S. (2019). Relative and absolute lung function change in a general population aged 60–102 years. European Respiratory Journal, 53(3), 1701812. View source version on Contacts PureTech Public Relationspublicrelations@ Investor Relationsir@ UK/EU MediaBen Atwell, Rob Winder+44 (0) 20 3727 1000puretech@ US MediaJustin Chen+1 609 578 7230jchen@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
20-05-2025
- Business
- Business Wire
PureTech's Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial
BOSTON--(BUSINESS WIRE)-- PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the successful Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone's treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF). 'The ELEVATE IPF trial is one of the most promising Phase 2 studies we've seen in IPF in recent years,' said Toby Maher, M.D., Ph.D., Professor of Medicine and Director of Interstitial Lung Disease at Keck School of Medicine, University of Southern California, Los Angeles, and lead investigator in the ELEVATE IPF trial. 'The ability for a monotherapy to reduce lung function decline close to a level seen in healthy older adults, and to sustain that effect over time without compromising tolerability, is not something we have seen with currently available therapies. Deupirfenidone has the potential to raise the bar for what patients and physicians can expect from IPF treatment.' Data presented from PureTech's global Phase 2b randomized, double-blind, active- and placebo-controlled, dose-ranging ELEVATE IPF trial demonstrated the potential for deupirfenidone to offer a differentiated treatment option for patients with IPF. In the trial, patients treated with deupirfenidone 825 mg three times a day (TID) experienced a slower rate of lung function decline, 1 as measured by Forced Vital Capacity (FVC), at 26 weeks versus those who were treated with placebo (-21.5 mL vs. -112.5 mL, respectively; p=0.02). 2 This statistically significant difference represents a robust treatment effect versus placebo of 80.9% for deupirfenidone 825 mg TID as a monotherapy. This result compares favorably against the rate of decline in FVC observed in the trial among patients treated with pirfenidone 801 mg TID versus placebo (-51.6 mL vs. -112.5 mL, respectively), which was consistent with previously reported pirfenidone clinical trial data 3 and represents a treatment effect of 54.1%. Taken together, these results indicate that the treatment effect with deupirfenidone 825 mg TID was approximately 50% greater than that of pirfenidone 801 mg TID, based on their respective reductions in lung function decline versus placebo (80.9% vs. 54.1%). In addition to these findings, deupirfenidone 825 mg TID also demonstrated a statistically significant benefit in delaying time to IPF progression 4 compared to placebo (hazard ratio = 0.439; p=0.0023), further supporting the clinical relevance of the treatment effect. Importantly, the rate of FVC decline observed over 26 weeks with deupirfenidone 825 mg TID (-21.5 mL) was similar to the expected natural decline in lung function in healthy older adults (approximately -15.0 mL to -25.0 mL). 5,6 Furthermore, preliminary data from the ongoing open-label extension (OLE) study suggest that this treatment effect is durable out to at least 52 weeks. As of May 9, 2025, a total of 101 patients had received at least 52 weeks of treatment with deupirfenidone. Those in the deupirfenidone 825 mg TID arm experienced a decline in FVC of -32.8 mL over the 52-week period, 7 which is similar to the expected natural decline in lung function in healthy older adults over one year (approximately -30.0 mL to -50.0 mL). 6 These new data provide additional support for the durability of the treatment effect observed with this dose and reinforce its potential to stabilize lung function decline over time, while maintaining favorable safety and tolerability. Additional details from the ongoing OLE are expected to be shared in a future scientific forum. These results are further supported by preliminary pharmacokinetic (PK) data, which underscore the differentiated profile of deupirfenidone. Compared to pirfenidone 801 mg TID, deupirfenidone 825 mg TID resulted in an approximately 50% increase in drug exposure. Notably, the dramatically increased drug exposure did not result in an increase in tolerability challenges, suggesting that the deuterated structure of deupirfenidone may overcome the dose-limiting adverse events associated with pirfenidone. PureTech believes these PK results are consistent with the enhanced efficacy and favorable tolerability seen with deupirfenidone 825 mg TID in the trial. 'The IPF community has long needed therapies that can provide meaningful efficacy without compromising tolerability,' said Bharatt Chowrira, Ph.D., J.D., Chief Executive Officer of PureTech. 'Data from our Phase 2b trial and open-label extension study suggest that deupirfenidone may slow lung function decline in a way that more closely mirrors the natural aging process, and that this effect is durable. These data are quite remarkable and – to our knowledge – this level of efficacy has not been observed with other monotherapies. These findings further support our belief that deupirfenidone may offer a substantially differentiated treatment option for people living with IPF and support its potential to become a new standard of care.' Deupirfenidone was well tolerated at both doses studied. Safety analyses included identification of the 16 most common treatment-emergent adverse events (TEAEs), defined as occurring in more than 5% of participants in at least one treatment group, and characterized the arm with the highest relative incidence of each of these 16 TEAEs. The pirfenidone 801 mg treatment group had the highest relative incidence for 9 of these TEAEs, followed by deupirfenidone 825 mg (5), placebo (2), and deupirfenidone 550 mg (0). 'The results of the ELEVATE IPF trial demonstrate the potential for deupirfenidone to address the persistent suboptimal efficacy offered by current standard-of-care treatments for IPF, without sacrificing tolerability,' Camilla Graham, M.D., M.P.H., Senior Vice President of Medical Affairs at PureTech. 'We are excited to continue development of deupirfenidone to meaningfully improve the lives of patients living with IPF.' PureTech is targeting a meeting with the U.S. Food and Drug Administration by the end of the third quarter of 2025 to discuss the results of the Phase 2b trial and align on a potential registrational pathway, with the goal of initiating a Phase 3 trial by the end of 2025. PureTech anticipates providing further guidance later this year following the finalization of the trial design and FDA interactions. About the ELEVATE IPF Trial The Phase 2b ELEVATE IPF trial was a global, randomized, double-blind, active- and placebo-controlled, dose-ranging trial designed to evaluate the efficacy, tolerability, safety and dosing regimen of deupirfenidone (LYT-100) in patients with IPF compared to placebo. 257 participants were randomized in a ratio of 1:1:1:1 to receive either 550 mg of deupirfenidone, 825 mg of deupirfenidone, 801 mg pirfenidone or placebo three times a day (TID) for 26 weeks. Participants who completed the trial had the option to enroll in an open-label extension, which is ongoing. The primary endpoint of the trial was the rate of decline in Forced Vital Capacity (FVC) for the combined deupirfenidone arms versus placebo over the 26-week treatment period. FVC is a measure of the maximum amount of air (in mL) that an individual can forcibly exhale after fully inhaling. It is a standard measurement in clinical trials for IPF and is used to assess disease progression as well as to predict mortality. A prespecified Bayesian analysis was utilized to assess the primary endpoint and provided a posterior probability, which is the probability of superior efficacy for deupirfenidone compared to placebo. This also allowed for augmentation of the placebo arm with placebo data from historical IPF trials. This approach enabled a more patient-centric clinical trial design by minimizing the number of trial participants exposed to placebo – a key consideration since IPF is progressive and fatal – while delivering a robust, placebo-controlled dataset. About Deupirfenidone (LYT-100) Deupirfenidone (LYT-100) is an investigational therapy in development as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). It is a deuterated form of pirfenidone, which – along with nintedanib – is one of the two FDA-approved treatments for IPF. Despite achieving blockbuster status, the current SOC treatments only modestly slow lung function decline, with tolerability limiting the ability to achieve higher doses. This results in suboptimal efficacy, reduced patient uptake, and poor adherence – all due to a tolerability ceiling that prevents dosing levels that could significantly improve patient outcomes. Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining safety and tolerability – a result not previously achieved by other investigational or marketed IPF therapies to the Company's knowledge. These findings support the potential for deupirfenidone to offer a meaningful advance for patients living with this progressive and life-limiting disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic diseases, including progressive fibrosing interstitial lung diseases and other fibrotic conditions. About Idiopathic Pulmonary Fibrosis (IPF) Idiopathic Pulmonary Fibrosis (IPF) is a rare, progressive and fatal lung disease characterized by irreversible scarring of lung tissue. Median survival following diagnosis is estimated to be two to five years. 8 IPF affects more than 230,000 people across the United States and EU5 (France, Germany, Italy, Spain, and the United Kingdom). 9 Although two therapies are approved to treat IPF, their use remains limited, and nearly three out of four people with IPF in the United States have never received either treatment. 10 There remains a significant need for therapies that can more effectively slow or stabilize disease progression, while maintaining favorable tolerability, to improve outcomes for people living with IPF. About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. Cautionary Note Regarding Forward-Looking Statements This press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation those related to the deupirfenidone (LYT-100) development program and development plans, its potential benefits to patients, plans for discussions with regulatory authorities, the further development of the program, future presentation of additional data from the trial and our future prospects, developments and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024, filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. References 1 Efficacy analysis used a random coefficient regression model with absolute FVC including baseline as response variable and week, treatment and interaction between week and treatment as fixed effect. The analysis was performed based on the predefined Full Analysis Set. 2 All p values are two-sided and have not been corrected for multiplicity. 3 Roche. (2014). Esbriet ® (pirfenidone) prescribing information. U.S. Food and Drug Administration. 4 IPF progression was defined as a ≥5% decline in FVCpp or death. 5 FVC decline at 6 months was estimated assuming linear decline over time. 6 Valenzuela, C., Bonella, F., Moor, C., Weimann, G., Miede, C., Stowasser, S., & Maher, T. (2024, September). Decline in forced vital capacity (FVC) in subjects with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) compared with healthy references [Poster presentation]. European Respiratory Society International Congress, Vienna, Austria; and Luoto, J., Pihlsgård, M., Wollmer, P., & Elmståhl, S. (2019). Relative and absolute lung function change in a general population aged 60–102 years. European Respiratory Journal, 53 (3), 1701812. Expand
